Co-Authors
This is a "connection" page, showing publications co-authored by IGNACIO IVAN WISTUBA and ADEL K EL-NAGGAR.
Connection Strength
0.260
-
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727.
Score: 0.057
-
PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2019 03; 41(3):615-622.
Score: 0.043
-
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
Score: 0.035
-
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46.
Score: 0.027
-
STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res. 2012 Jan 01; 18(1):127-39.
Score: 0.026
-
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010 Oct 21; 467(7318):986-90.
Score: 0.025
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.024
-
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
Score: 0.023